Name

Mariana Oncology

Legal name

Mariana Oncology Inc.

Website

https://marianaoncology.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industries

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Medical Oncology (HLAKAFAB), Thoracic (Lung) Oncology (HLAKAFAL), Radiopharmaceutical & Nuclear Medicine Distributors (HLAIAJAI)

Keywords

• Radiopharmaceutical development
• Radioligand therapy
• Precision oncology therapeutics
• Cancer drug development
• Peptide-based radiopharmaceuticals

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Infrastructure, Operations

Revenue model

1. Radiopharmaceutical Development: Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies for cancer treatment. The company has no commercial revenue as it is in the R&D phase. Following acquisition by Novartis in May 2024, it operates as a wholly-owned subsidiary, with R&D funded by Novartis.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Mariana Oncology is a biotechnology company developing precision radioligand therapies (RLTs) that combine tumor-targeting peptide ligands with therapeutic radioisotopes (alpha- and beta-emitting radionuclides) for the treatment of solid tumor cancers. Its lead clinical-stage program targets DLL3-expressing tumors including small cell lung cancer, with a second program against B7-H3, and an actinium-225 payload candidate (MC-339) for small cell lung cancer. The company maintains in-house GMP manufacturing capabilities and secured isotope supply to support rapid R&D and clinical development.

Product overview

Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company pioneering a new class of targeted peptide-based radiopharmaceuticals. The company's product portfolio consists of radioligand therapies (RLTs) combining tumor-targeting molecules (ligands) with therapeutic radioisotopes. The lead clinical-stage program is DLL3-Targeted Radioligand Therapy in Phase 1 trials, with a second program targeting B7-H3. Lead candidate MC-339 carries an actinium-225 payload for small cell lung cancer. The company has built in-house GMP capabilities and secured access to a broad radioisotope supply. Mariana Oncology operates as a subsidiary of Novartis following the May 2024 acquisition.

Differentiator

Problem solved

Functional benefit

Products and services

• DLL3-Targeted Radioligand Therapy Lead clinical-stage program targeting DLL3, a cell-surface protein widely expressed across a range of aggressive cancers with limited expression on healthy cells. Evaluated in a Phase 1 clinical trial for advanced DLL3-expressing tumors including small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, neuroendocrine prostate cancer, and large cell neuroendocrine carcinoma.
• B7-H3-Targeted Radioligand Therapy

Quantifiable outcome

• Phase 1 clinical trial initiated for DLL3-targeted program in advanced DLL3-expressing tumors (NCT07006727)

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• NovartisflagshipStrategic or Co-development Partner · 2 May 2024Acquired Mariana Oncology for $1 billion upfront plus up to $750 million in milestone payments. The acquisition brings together Mariana Oncology's innovative radiopharmaceutical pipeline and platform with Novartis's proven clinical development and commercialization expertise. Mariana operates as a wholly-owned subsidiary and serves as a primary research and drug discovery hub for Novartis's radioligand therapy R&D activities.

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• RayzeBio: RayzeBio was an actinium-225-based radiopharmaceutical developer acquired by Bristol-Myers Squibb in 2024 for ~$4.1B. Directly comparable as an actinium-225 RLT developer with clinical-stage oncology pipeline assets, also acquired by a big-pharma RLT consolidator.
• POINT Biopharma: POINT Biopharma was a clinical-stage radiopharmaceutical company developing PSMA-targeted and other RLTs, acquired by Eli Lilly in 2024 for ~$1.4B. Directly comparable as a clinical-stage RLT platform recently consolidated by big pharma.
• Fusion Pharmaceuticals: Fusion Pharmaceuticals developed actinium-225-based RLTs targeting solid tumors and was acquired by AstraZeneca in 2024 for ~$2.4B. Closely comparable to Mariana's Ac-225 platform, target approach, and acquisition-by-strategic trajectory.
• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company with PSMA imaging (Illuccix) and emerging RLT pipeline. Comparable as a developer of targeted radiopharmaceuticals for oncology with both diagnostic and therapeutic assets.

Emerging players

• Molecular Partners: Molecular Partners is developing radioligand therapies using Designed Ankyrin Repeat Protein (DARPin) technology for targeted cancer therapy. Comparable as an emerging oncology RLT developer using alternative targeting scaffolds versus antibodies.
• Aktis Oncology: Aktis Oncology is a private clinical-stage radiopharmaceutical company developing alpha-emitting RLTs for solid tumors. Comparable as an emerging actinium-based RLT developer targeting similar oncology indications.
• Convergent Therapeutics: Convergent Therapeutics is a clinical-stage radiopharmaceutical company developing PSMA-targeted RLTs for prostate cancer. Comparable as a clinical-stage RLT developer focused on solid tumor oncology.

Broad incumbents

• Novartis (Pluvicto/Lutathera): Novartis is the parent of Mariana Oncology and the leading commercial radioligand therapy company with Pluvicto (PMSA, Lu-177) and Lutathera. Directly comparable as a radioligand therapy platform with commercial-stage assets in adjacent indications.
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with diagnostic and therapeutic radioligand products (PNT2002, PNT2003 PSMA, Melanoma programs). Comparable as a broad radiopharmaceutical platform with both imaging and therapy assets.
• Bayer (Curium / Noria platform): Bayer has built a radiopharmaceutical platform through the Noria and Algeta acquisitions, with actinium-225 RLT programs in oncology. Comparable as a large pharmaceutical company developing actinium-225 RLTs for solid tumors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/marianaoncology

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mariana Oncology